Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe
SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe. Cenobamate is a novel, small molecule investigational antiepileptic drug for the potential treatment of partial-onset seizures in adult patients. Under the agreement, SK Biopharmaceuticals will receive an upfront payment of $100 million and is eligible to receive up to $430 million upon achievement of certain regulatory and commercial milestones in addition to royalties on net sales generated in Europe. SK Biopharmaceuticals will have an option to obtain a significant equity stake in Arvelle and will also retain commercial rights for all non-European territories. Cenobamate was discovered and developed by SK Biopharmaceuticals from inception through to the acceptance of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA).
“We are very pleased to enter into this licensing agreement with Arvelle, as it provides important validation of the global potential for cenobamate as a new treatment option for adults with partial-onset seizures,” said Dr. Jeong Woo Cho, President and CEO of SK Biopharmaceuticals. “Arvelle’s experienced leadership team and focus on CNS disorders make them the ideal partner to advance the development and commercialization of our compound in Europe.”
Arvelle Therapeutics is a newly created company that received one of the largest initial financing commitments for a European-focused biopharmaceutical company from a global syndicate of investors that include NovaQuest, LSP, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners. Mark Altmeyer has been named President and CEO of Arvelle. Altmeyer brings more than 30 years of global biopharmaceutical experience to Arvelle. As President and CEO of Otsuka America Pharmaceutical, Inc., Altmeyer oversaw the growth of Abilify® into a multi-billion-dollar product. Most recently, he served as President and Chief Commercial Officer of Axovant Sciences and previously led the neuroscience business unit at Bristol-Myers Squibb Company. Altmeyer is joined by a talented team of colleagues from Axovant with deep experience in CNS drug development and global commercialization. Arvelle intends to file a Marketing Authorization Application (MAA) for cenobamate for partial-onset seizures in adult patients based on the data generated from SK Biopharmaceuticals’ global clinical trial program.
“We launched Arvelle to bring truly innovative CNS products to patients suffering from serious neurological conditions and cenobamate is the perfect first pipeline product,” said Altmeyer. “Given the data generated in clinical trials and the FDA acceptance of the NDA, we believe cenobamate has the potential to be an important antiepileptic drug treatment option for adult patients suffering from partial-onset seizures. We appreciate the support and validation of our investors and are very enthusiastic about our potential in the European market.”
“We are very excited to invest in the talented team at Arvelle on this new venture,” said Martijn Kleijwegt, Managing Partner of LSP. “SK Biopharmaceuticals has done an excellent job on the discovery and development of cenobamate and we believe that Arvelle is the right company to gain EU approval for cenobamate and ultimately bring it to patients in Europe.”
About Cenobamate
Cenobamate (YKP3089) was discovered by SK Biopharmaceuticals and SK life science and is being investigated for the potential treatment of partial-onset seizures (also known as “focal seizures”) in adult patients. Cenobamate’s mechanism of action is not fully understood, but it is believed to work through two separate mechanisms: enhancing inhibitory currents through positive modulation of GABA-A receptors and decreasing excitatory currents by inhibiting the persistent sodium current.
Global trials for adults with partial-onset seizures are ongoing to evaluate cenobamate safety. An additional clinical trial is investigating cenobamate safety and efficacy for another form of epilepsy in adult patients.
The U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application for cenobamate for the potential treatment of partial-onset seizures in adults in February 2019.
Cenobamate is not approved by the FDA, European Medicines Agency (EMA) or any other regulatory authorities. Safety and efficacy have not been established.
About SK Biopharmaceuticals
SK Biopharmaceuticals is focused on research and development of treatments for disorders of central nervous system (CNS) and cancer. SK Biopharmaceuticals is an affiliate of SK Group, the second largest conglomerate in Korea.
Currently, SK Biopharmaceuticals is conducting basic research for the development of innovative new drugs at its research center in Pangyo, Gyeonggi Province, Korea. Further, the company is pursuing global clinical development and direct marketing through its U.S. subsidiary SK Life Science, Inc., in Fair Lawn, New Jersey, USA.
SK Biopharmaceuticals has a pipeline of eight compounds in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others. The first product the company is planning to commercialize, cenobamate (YKP3089), is an investigational compound for the potential treatment of partial-onset seizures in adult patients. The NDA for cenobamate for the potential treatment of partial-onset seizures in adult patients is currently under review by the FDA. For more information, visit SK Biopharmaceuticals’ website at www.skbp.com/eng.
About Arvelle Therapeutics
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received one of the largest initial financing commitments for a European-focused biopharmaceutical company with investments from a global syndicate including NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners. More information is available at http://arvelletx.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005290/en/
Contact information
For Arvelle Therapeutics:
Mike Beyer, Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
Tietoja julkaisijasta
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Scania’s New Intelligent C-me Vest on Display at MWC Barcelona by Imagimob and Light Flex20.2.2019 10:30:00 | Tiedote
Imagimob is pleased to announce that attendees of this year’s Mobile World Congress will get the chance to see Scania’s groundbreaking C-me safety vest, which officially hits the market this year. The intelligent and highly visible vest combines Imagimob Edge AI software with a unique active light technology system by Light Flex. The connected and intelligent C-me safety vest keeps a protective hand over truck drivers during work around vehicles. If something goes wrong—for example, the driver suddenly falls or becomes immobilized—a call for help is automatically triggered. Pre-assigned contacts are notified and sent GPS coordinates, and attention is immediately drawn to the driver through flashing light indicator activity. By using data from embedded sensors, Imagimob AI instantaneously analyzes the motion of the driver, lights up the vest whenever the driver exits the truck, and sends a signal when help is needed. The result is a considerable safety boost for truck drivers, who typic
Traxens Gains Confidence of Tens of Top 500 Beneficial Cargo Owners20.2.2019 10:00:00 | Tiedote
Traxens, expert in providing high-value data and services for the supply chain industry, today announces that it signed several contracts with some of the top 500 Beneficial Cargo Owners (BCO), including major companies such as BASF. Under the terms of the agreements, Traxens provides door-to-door data monitoring solutions for smart containers supplied by partnering shipping lines. BCOs are typically industrial companies importing and exporting large volumes of goods in containers. Traxens’ customers operate in various industries such as aeronautics, pharmaceuticals, chemicals, automotive and foods. These firms require cutting-edge data monitoring systems for easy and reliable management of stocks, actionable analytics and cost reductions. Traxens’ Supply Chain Diagnostic solution enables near real-time monitoring with custom alerts through its web application Traxens-Hub or direct back-end integration, as well as bespoke analysis of transportation performance, thus enabling process op
Guidewire Software Announces Hexaware as New Consulting Alliance Partner20.2.2019 00:15:00 | Tiedote
Hexaware Technologies, a fast growing automation-led, next generation provider of IT, BPO and consulting services, and Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced that Hexaware has joined Guidewire PartnerConnect™ as a Consulting alliance member at the Select level. With over 20 years’ experience working with P&C insurers, Hexaware has developed value-add solution and technology offerings that enable insurers to rapidly adopt Guidewire InsuranceSuite™ and Guidewire Digital products, increasing speed to implementation, mitigating execution risk, and lowering costs. Hexaware has supported Guidewire customer success in APAC and EMEA and offers localized solutions for insurers in these regions. “Digital technology is disrupting the P&C insurance industry at an unprecedented rate, and insurers are leveraging market-leading platforms, such as Guidewire InsurancePlatform™, to deliver differentiated pr
IFF Acquires The Additive Advantage; Expands Scent, Taste, and Actives Delivery Capabilities20.2.2019 00:15:00 | Tiedote
Regulatory News: International Flavors & Fragrances Inc. (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), has expanded and strengthened its innovation capabilities for scent, taste and active ingredients through the acquisition of The Additive Advantage (TAA), a company that develops novel technologies with diverse capabilities that span applications and industries. TAA has the expertise to develop the next-generation delivery systems technology platform that will enable the printing of flavors, fragrances, cosmetic and health & nutrition actives onto a variety of consumer products. IFF Chairman & CEO Andreas Fibig said, “The acquisition of TAA helps to expand our large portfolio of offerings to customers in a truly unique way – through print technology. With the expertise that this talented group of people brings under our roof, we envision taking delivery systems to a completely new level and ultimately enriching how consumers experience our customers’ products.” “We are genuinely exci
Rockwell Automation and Schlumberger Enter Joint Venture Agreement to Create Sensia, the Oil and Gas Industry’s First Fully Integrated Automation Solutions Provider20.2.2019 00:05:00 | Tiedote
Rockwell Automation (NYSE: ROK), the world’s largest company dedicated to industrial automation and information, and Schlumberger (NYSE: SLB), the world's leading provider of technology for reservoir characterization, drilling, production, and processing to the oil and gas industry, announced today that they have entered into an agreement to create a new joint venture, Sensia, the first fully integrated digital oilfield automation solutions provider. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190219005851/en/ The transaction is expected to close, and the joint venture is expected to begin serving customers, in the summer of 2019, subject to regulatory approvals and other customary conditions. The Sensia joint venture will be the first fully integrated provider of measurement solutions, domain expertise, and automation to the oil and gas industry. It will offer scalable, cloud and edge-enabled process automation, includin
IDEMIA Will Present Its 2018 Annual Financial Results to Investors on February 20, 201919.2.2019 19:07:00 | Tiedote
IDEMIA, the world leader in Augmented Identity, today announced that it will present its 2018 annual financial results to investors on Wednesday February 20, 2019. Yann Delabrière (CEO), Laurent Lemaire (CFO), and Frédéric Beylier (COO) will be presenting the financial results and taking questions the same day at 4:00 pm CET (3:00 pm London Time / 10:00 am New York Time). For more information, please refer to our website: http://investors.oberthur.com About IDEMIA IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect, travel and vote), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.
Tutustu uutishuoneeseemme